SCHEMBL955388

SCHEMBL955388

COc1cccc(OC)c1COc1cccc(CC(=O)O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 1/20 0.51
MRGPRX4 Q96LA9 2/20 0.49
GAA P10253 2/20 0.49
ALDH1A1 P00352 1/20 0.49
TSHR P16473 1/20 0.49
NFKB1 P19838 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
PLA2G4B P0C869 1/20 0.48
MAOB P27338 2/20 0.48
LTB4R Q15722 1/20 0.47
LTB4R2 Q9NPC1 1/20 0.47
CTBP2 P56545 1/20 0.47
LMNA P02545 1/20 0.47
CFD P00746 1/20 0.46
PPARD Q03181 1/20 0.46
NR1H3 Q13133 1/20 0.46
PTGS1 P23219 1/20 0.46
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
BCHE P06276 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008537 0.84 PPARA (0.47) MRGPRX4TSHRTDP1MAOBLTB4R
SCHEMBL957978 0.83 SLC22A12 (0.68) SLC22A12PLA2G4BMAOBLTB4RLTB4R2
SCHEMBL1760801 0.81 PPARD (0.49) SLC22A12GAATSHRNFKB1TDP1
SCHEMBL954459 0.81 NR4A2 (0.66) ALDH1A1TSHRMAOBLTB4RLTB4R2
SCHEMBL229067 0.80 PTGS1 (0.67) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL29824310 0.80 PTGS1 (0.67) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL955741 0.80 PPARD (0.48) SLC22A12MRGPRX4ALDH1A1TSHRTDP1
Hydrochloric Acid SCHEMBL8693464 0.79 CTBP2 (0.65) ALDH1A1CTBP2LMNAPTGS1AKR1C3
SCHEMBL8218805 0.79 CTBP2 (0.65) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL3901473 0.78 FFAR1 (0.54) MRGPRX4PLA2G4BLTB4RLTB4R2CTBP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP claimed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US claimed
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2013-10-03 US claimed
CN-101969773-A compounds and methods for reducing uric acid WELLSTAT THERAPEUTICS CORP 2011-02-09 CN claimed
US-20110014176-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2011-01-20 US claimed
EP-2268141-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2011-01-05 EP claimed
WO-2009151695-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2009-12-17 WO claimed
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP disclosed
EP-2268141-B1 COMPOUND AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORP (US) 2019-05-08 EP disclosed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US disclosed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US disclosed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US disclosed
CN-102976928-B Compounds for reducing uric acid WELLSTAT THERAPEUTICS CORP 2014-09-17 CN disclosed
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2013-10-03 US disclosed
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2013-10-03 US disclosed
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2013-10-03 US disclosed
CN-102976928-A Compounds for reducing uric acid WELLSTAT THERAPEUTICS CORP 2013-03-20 CN disclosed
CN-101969773-A compounds and methods for reducing uric acid WELLSTAT THERAPEUTICS CORP 2011-02-09 CN disclosed
EP-2268141-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2011-01-05 EP disclosed
WO-2009151695-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID RCC2, HAX1, SLC10A6 SLC22A12 139/4885MRGPRX4 1727/4885GAA 3963/4885
US-20110014176-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID UGP2, TAS2R46, PYCARD SLC22A12 257/4885MRGPRX4 1966/4885GAA 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.